AVVie
Vienna
About AVVie
AVVie GmbH is a medical device start up focusing on the development of minimally invasive implants for heart valve repair. Mitral regurgitation occurs when the mitral valve leaflets do not close properly. While small leaks are usually not considered a problem, more severe cases weaken the heart over time and can lead to heart failure. The Mitral Butterfly® implant is deployed by means of a catheter (thin tube) through the vascular system onto the beating heart, thereby eliminating the need for open-heart surgery. The treatment can reduce costs due to shortened hospitalization times and may be available to non-option patients, along with younger, healthier patients. The AVVie product has clear advantages over their competitors; a one-stage delivery, as opposed to a complicated multiple-stage delivery, and a physiological design, where the leaflets continue to function in a normal pattern post-implantation. Repair of the diseased valve takes less than 12 minutes.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $2.4M
- Last round: Grant (Oct 2022)
- Website: angelvalve.com
Industries & Categories
Health Care, Manufacturing, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/avvie-38948 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.